Eli Lilly’s oral GLP‑1 candidate orforglipron met primary and key secondary endpoints in the Phase 3 Attain‑Maintain trial, demonstrating superior weight‑maintenance versus placebo over 52 weeks after patients had lost weight on injectable GLP‑1 therapies. The company has formally asked the FDA for approval and received one of the agency’s expedited "national priority" review vouchers that shortens the timeline for a decision. Trial data showed orforglipron reduced weight regain compared with placebo and may address an unmet need around long‑term maintenance after injectable therapy. The quick review could give Lilly a commercial edge against rivals developing oral obesity drugs; details on magnitude of effect, safety, and positioning versus injectables will determine clinical uptake.